Comparative Pharmacology
Head-to-head clinical analysis: CARBOPLATIN versus NEOSAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBOPLATIN versus NEOSAR.
CARBOPLATIN vs NEOSAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carboplatin forms platinum-DNA adducts, causing intrastrand crosslinks and G2/M cell cycle arrest, leading to apoptosis.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
IV infusion over 15-60 minutes, target AUC 4-6 using Calvert formula (dose = target AUC × (GFR + 25)). Adults: typical initial dose 400 mg/m² every 4 weeks or AUC 5-6 every 3-4 weeks.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
None Documented
None Documented
Terminal elimination half-life: 2.6-5.9 hours in adults with normal renal function. In patients with creatinine clearance <60 mL/min, half-life is prolonged (up to 17-26 hours). Clinically, dosing adjustments are required based on Calvert formula using glomerular filtration rate.
Clinical Note
moderateCarboplatin + Digoxin
"Carboplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCarboplatin + Digitoxin
"Carboplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCarboplatin + Deslanoside
"Carboplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCarboplatin + Acetyldigitoxin
"Carboplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Renal: ~65% of platinum excreted in urine within 24 hours, primarily as unchanged carboplatin; ~32% as metabolites. Biliary/fecal excretion is minimal (<6%).
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Category D/X
Category C
Alkylating Agent
Alkylating Agent